In this episode, Dr. Gandolfo addresses a compelling question from a listener who is curious about the use of GLP-1 drugs, such as Ozempic and Mounjaro, in patients with inflammatory bowel diseases like Crohn's and ulcerative colitis. Dr. Gandolfo provides a comprehensive overview of GLP-1 drugs, explaining how they function as agonists to stimulate insulin secretion and promote weight loss by altering gut motility and suppressing appetite. Delving into the potential implications for patients with inflammatory bowel disease, Dr. Gandolfo explores recent studies suggesting that GLP-1 drugs might be well-tolerated and could even offer benefits in reducing bowel frequency for patients who have undergone colectomy. While these findings are promising, he emphasizes the need for further human studies to confirm these effects. Dr. Gandolfo also addresses common side effects associated with GLP-1 drugs, such as nausea, and reassures listeners about the overall safety of these medications. He highlights the importance of discussing individual risks and benefits with a healthcare provider before starting any new treatment. Referenced in this episode: DDW abstract on safety of GLP-1 drugs with IBD Study of GLP-1 drugs and risk of IBD flare GLP-1 drugs and possible mechanism of benefit in IBD patients Pilot study using GLP-1 agonist to reduce diarrhea in colectomy patients Review of mechanism of action of GLP-1 Be sure to subscribe to The Real GI Doc Show for more insights, and reach out with your questions on social media @realgidoc or leave an audio question for Dr. Gandolfo here. Find The Real GI Doc Show on social media, join the newsletter, read Dr. Gandolfo's bio, or ask a question using this link. Watch this episode on The Real GI Doc Show YouTube channel!